Breast cancer management : application of clinical and translational evidence to patient care /
| Other Authors: | |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
Philadelphia :
Lippincott Williams & Wilkins,
[2003]
|
| Edition: | Second edition. |
| Subjects: |
Table of Contents:
- Pt. I. Treatment recommendations for specific stages of breast cancer
- Sec. 1. Early stage disease: radiation
- Radiation therapy for breast cancer: radiotherapy techniques to decrease treatment morbidity
- The role of radiation therapy in breast cancer management
- Survival impact of locoregional radiation in stage I-II breast cancer: evidence-based review
- Sec. 2. Early stage disease-surgery, chemotherapy, and hormones
- Evolution in the management of ductal carcinoma in situ through randomized clinical trials
- Should surgeons abandon a routine axillary dissection for sentinel node biopsy in early breast cancer?
- Surgical consideration in breast cancer patients treated with preoperative chemotherapy
- The medical oncology perspective on preoperative chemotherapy for early operable breast cancer
- Adjuvant treatment: node-negative breast cancer
- Node-positive breast cancer
- Sec. 3. Metastatic disease: chemotherapy
- The taxanes: paclitaxel and docetaxel
- Capecitabine
- Vinorelbine
- Liposomal doxorubicin in the treatment of metastatic breast cancer
- High-dose chemotherapy and autologus stem cell transplantation for metastatic breast cancer
- Sec. 4. Metastatic disease: hormone treatment
- Aromatase inhibitors in the treatment of breast cancer
- New antiestrogens: modulators of estrogen action
- Pt. II. Translational approaches: current, planned, and most promising
- Sec. 1. Current
- HER2/neu and trastuzumab
- Low-dose metronomic antiangiogenic chemotherapy: preclinical and clinical applications in breast cancer
- Epidermal growth factor receptor: biology and new therapeutics
- Dimming the blood tide: angiogenesis, anti-angiogenic therapy and breast cancer
- Results from a phase 1 trial of E1A gene therapy in breast and ovarian cancer: what's next
- Sec. 2. DNA microarray analysis of breast cancer: toward customized anti-cancer drug therapy and rational drug design
- Proteomics of breast cancer: marker discovery and signal pathway profiling
- Steroid and growth factor receptors: cross-talk and clinical implications
- Cell cycle inhibitors in the treatment of breast cancer
- Predictive molecular markers: a new window of opportunity in the adjuvant therapy of breast cancer
- Pt. III. Anatomapathology and the metastatic process
- Basic biology of the metastatic process: clinical implications
- Prognostic and predictive factors in breast cancer: an evidence-based medicine approach
- Prognostic factors in invasive breast cancer using histology
- Pt. IV. Issues for the practicing oncologist
- Sec. 1. Supportive care and quality of life
- Science and alternative therapy: the past, present and future
- Ethics and hereditary cancer: issues for women and families with hereditary breast/ovarian cancer
- Hematopoietic growth factor support in breast cancer
- Erythropoietin in the management of cancer patients
- The place of bisphosphonates in the management of breast cancer
- Cutaneous metastasis and malignant wounds
- Chemotherapy-induced nausea and vomiting
- Quality of life data interpretation: an update on key issues in advanced breast cancer
- The internet, the evidence and the health consumer
- Sec. 2. Prevention and screening
- Breast screening
- Chemoprevention studies in Italy and the United Kingdom
- Breast cancer prevention: the U.S. viewpoint
- Pt. V. Clinical data analysis: current and future standards
- Evidence analysis: historical and contemporary perspectives
- Clinical practice guidelines
- RECIST: response evaluation criteria in solid tumors
- Need for large-scale randomized evidence to assess moderate benefits reliably
- Economic evaluation analysis in breast cancer therapy: from evidence to practice
- Pt. VI. High-dose chemotherapy
- High-dose chemotherapy in the adjuvant therapy of breast cancer: the argument for further investigation
- Pt. VII. Summary statement
- The future of breast cancer medicine